These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11918622)

  • 21. Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model.
    Shinozaki T; Matsuyama Y; Iimuro S; Umegaki H; Sakurai T; Araki A; Ohashi Y; Ito H;
    Geriatr Gerontol Int; 2012 Apr; 12 Suppl 1():88-102. PubMed ID: 22435944
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes.
    Betteridge DJ; Gibson JM
    Diabet Med; 2007 May; 24(5):541-9. PubMed ID: 17367312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Total and low-density lipoprotein cholesterol in high-risk patients treated with atorvastatin monotherapy in the United Kingdom: analysis of a primary-care database.
    Jameson K; Zhang Q; Zhao C; Ramey DR; Tershakovec AM; Gutkin SW; Marrett E
    Curr Med Res Opin; 2014 Apr; 30(4):655-65. PubMed ID: 24495126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
    Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
    Lancet; 2003 Apr; 361(9364):1149-58. PubMed ID: 12686036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
    Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
    Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
    Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
    J Am Coll Cardiol; 2008 Apr; 51(15):1448-54. PubMed ID: 18402899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.
    Athyros VG; Papageorgiou AA; Athyrou VV; Demitriadis DS; Kontopoulos AG
    Diabetes Care; 2002 Jul; 25(7):1198-202. PubMed ID: 12087019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
    Yee HS; Fong NT
    Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).
    Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Fuller JH;
    Diabetologia; 2005 Dec; 48(12):2482-5. PubMed ID: 16284747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
    Schwartz GG; Olsson AG; Ezekowitz MD; Ganz P; Oliver MF; Waters D; Zeiher A; Chaitman BR; Leslie S; Stern T;
    JAMA; 2001 Apr; 285(13):1711-8. PubMed ID: 11277825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The CARDS trial: diabetic patients dealt a winning hand.
    Armani A; Toth PP
    Curr Atheroscler Rep; 2006 Sep; 8(5):429-32. PubMed ID: 16901414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evaluating the efficacy and tolerance of atorvastatin in hyperlipidemia in general practice (SWITCH Study)].
    Noseda G; Darioli R; Keller U; Mordasini R; Shokry A; Schaffhauser B; Riesen W
    Schweiz Med Wochenschr; 2000 Jun; 130(23):889-95. PubMed ID: 10897490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insulin resistance syndrome and type 2 diabetes mellitus.
    Erkelens DW
    Am J Cardiol; 2001 Oct; 88(7B):38J-42J. PubMed ID: 11595198
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
    Sever PS; Poulter NR; Dahlöf B; Wedel H; Collins R; Beevers G; Caulfield M; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J
    Diabetes Care; 2005 May; 28(5):1151-7. PubMed ID: 15855581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting targets for LDL-lowering therapy: lessons from the Collaborative Atorvastatin Diabetes Study (CARDS).
    Sniderman A; Solhpour A
    Clin Chem; 2009 Mar; 55(3):391-3. PubMed ID: 19147725
    [No Abstract]   [Full Text] [Related]  

  • 37. Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.
    Iovine C; Lilli S; Gentile A; Patti L; Di Marino L; Cipriano P; Riccardi G; Rivellese AA
    Eur J Clin Invest; 2006 Aug; 36(8):560-5. PubMed ID: 16893378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [CARDS confirms usefulness of LDL lowering in type 2 diabetics].
    Bern VH
    Praxis (Bern 1994); 2004 Oct; 93(44):1 p following 1830. PubMed ID: 15559908
    [No Abstract]   [Full Text] [Related]  

  • 39. Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS).
    Charlton-Menys V; Betteridge DJ; Colhoun H; Fuller J; France M; Hitman GA; Livingstone SJ; Neil HA; Newman CB; Szarek M; DeMicco DA; Durrington PN
    Diabetologia; 2009 Feb; 52(2):218-25. PubMed ID: 18972097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study.
    Aguilar-Salinas CA; Gómez-Pérez FJ; Posadas-Romero C; Vázquez-Chávez C; Meaney E; Gulías-Herrero A; Guillén LE; Alvarado Vega A; Mendoza Pérez E; Eduardo Romero-Nava L; Angélica Gómez-Díaz R; Salinas-Orozco S; Moguel R; Novoa G
    Atherosclerosis; 2000 Oct; 152(2):489-96. PubMed ID: 10998478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.